A carregar...
BTK inhibitors in cancer patients with COVID19: “The winner will be the one who controls that chaos” (Napoleon Bonaparte)
As the SARS-CoV-2 (COVID19) pandemic spreads and the number of Bruton’s tyrosine kinase inhibitor (BTKi)-treated COVID19 affected patients grows, we must consider the pros and cons of BTKi discontinuation for our patients. In favor of BTKi continuation, BTK plays an active role in macrophage polariz...
Na minha lista:
| Publicado no: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7367762/ https://ncbi.nlm.nih.gov/pubmed/32345646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-1427 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|